Molluscum contagiosum

Ligand Acquires Assets of Novan, Inc. for $12.2 Million

Retrieved on: 
Wednesday, September 27, 2023
Biotechnology, General Health, Pharmaceutical, Health, New Drug Application, Novin, United States bankruptcy court, Bayer, Molluscum contagiosum, PDUFA, First Ever, Bankruptcy, Cryptocurrency, Ligand

On July 17, 2023, Ligand offered $15 million to acquire all of the assets of Novan as well as to provide up to $15 million in debtor-in-possession (“DIP”) financing.

Key Points: 
  • On July 17, 2023, Ligand offered $15 million to acquire all of the assets of Novan as well as to provide up to $15 million in debtor-in-possession (“DIP”) financing.
  • In September 2023, the Bankruptcy Court approved a $12.2 million bid from Ligand to purchase berdazimer gel and all the assets related to the NITRICIL™ technology platform, and the rights to the Bayer-partnered Sitavig program.
  • The approved $12.2 million bid was credited to the $15 million DIP financing, with the balance of $2.8 million and accrued interest repaid to Ligand.
  • “We are pleased with the outcome of the bankruptcy proceeding resulting in Ligand’s full ownership of berdazimer gel, NITRICIL platform and related assets.

Verrica Pharmaceuticals to Host Virtual KOL Event Discussing the Approval of YCANTH™ (Cantharidin) Topical Solution for the Treatment of Molluscum on October 11, 2023

Retrieved on: 
Wednesday, September 27, 2023
KOL, Therapy, Fungal infection, Pediatric Dermatology, Inflammation, Pain, Itch, Mercedes Gonzalez, Sibling, Patient, Molluscum contagiosum, Fomite, Genetically modified bacteria, FDA, Skin, Vaccine, Dermatology, MD

The event will focus on the recent approval of YCANTH™ as the only product approved by the FDA to treat molluscum in adult and pediatric patients two years of age and older.

Key Points: 
  • The event will focus on the recent approval of YCANTH™ as the only product approved by the FDA to treat molluscum in adult and pediatric patients two years of age and older.
  • Molluscum is caused by a pox virus that produces distinctive raised, skin-toned-to-pink-colored lesions that can cause pain, inflammation, itching and bacterial infection.
  • It is easily transmitted through direct skin-to-skin contact or through fomites and can spread to other parts of the body or to other people, including siblings.
  • Without treatment, molluscum can last for an average of 13 months, and in some cases, up to five years.

Nufactor® Announces its Partnership with Verrica Pharmaceuticals to be the Exclusive Specialty Pharmacy to Provide YCANTH™, the First FDA Approved Treatment for Molluscum Contagiosum

Retrieved on: 
Tuesday, August 29, 2023
Swimming, Partnership, Face, Food, Neck, Stomach, School, Patient, Molluscum contagiosum, FDA, Health, Regulation of tobacco by the U.S. Food and Drug Administration, Skin

The U.S. Food and Drug Administration (FDA) describes molluscum contagiosum as “a viral skin infection that can cause white, pink, or flesh-colored bumps that may itch or become irritated.

Key Points: 
  • The U.S. Food and Drug Administration (FDA) describes molluscum contagiosum as “a viral skin infection that can cause white, pink, or flesh-colored bumps that may itch or become irritated.
  • These bumps can happen alone or in groups almost anywhere on the skin, including the face, neck, arms, legs, stomach, and genital area.
  • The FDA found that YCANTH is a safe and effective topical treatment for patients as young as two years old.
  • "Verrica Pharmaceuticals saw an unmet need for patients—predominantly children—with molluscum contagiosum, and Nufactor is honored to be their partner in helping healthcare providers and patients access YCANTH.

FFF Enterprises Announces its Partnership with Verrica Pharmaceuticals to be the Exclusive Distributor of YCANTH™, the First FDA Approved Treatment for Molluscum Contagiosum

Retrieved on: 
Tuesday, August 29, 2023
Swimming, FFF, Face, Health care, Food, Research, Neck, Stomach, School, Patient, Molluscum contagiosum, Physician, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Skin, Pharmaceutical industry

The U.S. Food and Drug Administration (FDA) describes molluscum contagiosum as “a viral skin infection that can cause white, pink, or flesh-colored bumps that may itch or become irritated.

Key Points: 
  • The U.S. Food and Drug Administration (FDA) describes molluscum contagiosum as “a viral skin infection that can cause white, pink, or flesh-colored bumps that may itch or become irritated.
  • These bumps can happen alone or in groups almost anywhere on the skin, including the face, neck, arms, legs, stomach, and genital area.
  • The FDA found that YCANTH is a safe and effective topical treatment for patients as young as two years old.
  • “Before the FDA approval of YCANTH, there was a significant unmet need for patients—often children—and their healthcare providers.

Verrica Pharmaceuticals Announces First Sale of YCANTH™ to FFF Enterprises

Retrieved on: 
Thursday, August 24, 2023
FFF, Partnership, Therapy, Fungal infection, WEST, Sale, Dermatology, Patient, Molluscum contagiosum, FDA, Skin, Pharmaceutical industry

WEST CHESTER, Pa., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the first commercial sale of YCANTH™ to its exclusive distributor, FFF Enterprises Inc. (“FFF”).

Key Points: 
  • YCANTH™ is the first and only FDA-approved treatment for molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children
    WEST CHESTER, Pa., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the first commercial sale of YCANTH™ to its exclusive distributor, FFF Enterprises Inc. (“FFF”).
  • “We are pleased to announce the first commercial sale of YCANTH™ to our exclusive distribution partner FFF Enterprises,” said Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals.
  • “As the first FDA-approved product to treat molluscum, YCANTH™ clearly addresses a significant unmet need for the millions of children and adults with this viral skin disease.
  • “With our sales and marketing team fully in place, we are excited to work in partnership with FFF so this large and underserved patient population can benefit from YCANTH™ therapy.”

Verrica Issues Statement in Support of FDA’s Warning Letters to Manufacturers and Retailers for Producing and Selling Unapproved Products for the Treatment of Molluscum Contagiosum

Retrieved on: 
Wednesday, August 23, 2023
Viral, Molluscum contagiosum, Dermatology, FDA, WEST, Therapy, Skin, Food, Pharmaceutical industry

WEST CHESTER, Pa., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, issued a statement today in support of the U.S. Food and Drug Administration’s (“FDA’s”) recent action against retailers and manufacturers of unapproved products for the treatment of molluscum contagiosum.

Key Points: 
  • Verrica’s product YCANTH™ is the first and only FDA-approved treatment for molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children
    WEST CHESTER, Pa., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, issued a statement today in support of the U.S. Food and Drug Administration’s (“FDA’s”) recent action against retailers and manufacturers of unapproved products for the treatment of molluscum contagiosum.
  • “On the heels of the June 1, 2023 FDA warning to consumers not to use unapproved products for the treatment of molluscum contagiosum, we are pleased the FDA is taking additional measures against these unapproved products,” said Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals.
  • “It is clear that the FDA views molluscum as a serious health problem that requires medical intervention with therapies that have been rigorously tested and properly reviewed.
  • Verrica has conducted two Phase 3 trials to demonstrate the clinical safety and efficacy of YCANTH™, so that the millions of people, primarily children, who suffer from this viral infection can finally receive a safe, effective, and FDA-approved treatment for their condition.”

Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results

Retrieved on: 
Tuesday, August 8, 2023
Therapy, Table, OrbiMed, WEST, Bank statement, Phase II, Wart, CMC, GAAP, Part, H.262/MPEG-2 Part 2, Dermatology, Patient, Molluscum contagiosum, Part Two, Research, FDA, Carcinoma, Skin, Vaccine, Pharmaceutical industry, Cryptocurrency, Reinsurance, Bank

– In July, FDA approved YCANTH™ for the treatment of molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children –

Key Points: 
  • – In July, FDA approved YCANTH™ for the treatment of molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children –
    WEST CHESTER, Pa., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the second quarter ended June 30, 2023.
  • Verrica recognized collaboration revenues of $0.2 million in the second quarter of 2023 and 2022 related to the Clinical Supply Agreement with Torii Pharmaceutical Col, Ltd (Torii).
  • Research and development expenses were $5.7 million in the second quarter of 2023, compared to $3.9 million for the same period in 2022.
  • General and administrative expenses were $5.9 million in the second quarter of 2023, compared to $5.2 million for the same period in 2022.

Following FDA Approval of YCANTH™ for the Treatment of Molluscum Contagiosum, Verrica Pharmaceuticals Enters into Non-Binding Term Sheet for up to $125 Million Debt Financing; Company to Host Conference Call and Webcast This Morning at 8:30 am ET

Retrieved on: 
Monday, July 24, 2023
GMP, Term sheet, Cantharidin, Therapy, SOFR, Pain, Dermatology, Erythema, Patient, Molluscum contagiosum, Itch, SPA, Webcast, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Food, City of Fresno discolored water investigation, Skin, Pharmaceutical industry

The facility is a five-year term loan that matures in July 2028.

Key Points: 
  • The facility is a five-year term loan that matures in July 2028.
  • Later this morning, the Company will host a conference call and webcast at 8:30 a.m.
  • The conference call dial-in numbers are (877) 407-4018 (domestic) or (201) 689-8471 (international) and the access code is 13740240.
  • The discontinuation rate due to an adverse reaction was 2.3% among subjects treated with YCANTH™ and 0.5% among subjects treated with vehicle.

Verrica Pharmaceuticals Announces FDA Approval of YCANTH™ (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum Contagiosum

Retrieved on: 
Friday, July 21, 2023
GMP, Skin discoloration, Swimming, Cantharidin, Therapy, Food and Drug Administration, Pain, School, Dermatology, Erythema, Patient, Molluscum contagiosum, Physician, Itch, FDA, Safety, Food, Caregiver, Skin, Vaccine, Pharmaceutical industry

WEST CHESTER, Pa., July 21, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced U.S. Food and Drug Administration (FDA) approval of YCANTH™ (cantharidin) topical solution for the treatment of molluscum contagiosum (molluscum) in adult and pediatric patients 2 years of age and older.

Key Points: 
  • ET –
    WEST CHESTER, Pa., July 21, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced U.S. Food and Drug Administration (FDA) approval of YCANTH™ (cantharidin) topical solution for the treatment of molluscum contagiosum (molluscum) in adult and pediatric patients 2 years of age and older.
  • Molluscum, which primarily affects children, is highly contagious and is commonly transmitted in households, schools, swimming pools and other extra-curricular settings.
  • Since molluscum spreads through skin-to-skin contact and the sharing of contaminated objects with its viral lesions, a topical treatment with precise administration is essential towards preventing further transmission.
  • The webcast can be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com .

Ligand Offers $15 Million to Acquire Assets of Novan, Inc.

Retrieved on: 
Monday, July 17, 2023
Infectious Diseases, Biotechnology, Pharmaceutical, Health, EPI, Fungal infection, Chapter 11, Title 11, United States Code, DIP, Sale, Stalking, Food and Drug Administration, Acquisition, Molluscum contagiosum, PDUFA, FDA, Food, Bankruptcy, Cryptocurrency, Credit, Novin, Ligand

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it has made an offer to acquire the assets of Novan, Inc. (Nasdaq: NOVN) (“Novan”) for $15 million in cash and provide up to $15 million in DIP financing to Novan inclusive of a $3 million bridge loan already funded.

Key Points: 
  • Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it has made an offer to acquire the assets of Novan, Inc. (Nasdaq: NOVN) (“Novan”) for $15 million in cash and provide up to $15 million in DIP financing to Novan inclusive of a $3 million bridge loan already funded.
  • Novan announced earlier today that it has filed for Chapter 11 reorganization and its entry into a stalking horse acquisition offer with Ligand.
  • The transaction is designed to preserve and maximize the value of Novan’s commercial business and berdazimer gel development assets.
  • We are well positioned to take advantage of opportunities such as the proposed acquisition of Novan’s assets,” said Todd Davis, CEO of Ligand.